Stiedl Oliver, Meyer Michael, Jahn Olaf, Ogren Sven Ove, Spiess Joachim
Department of Developmental and Behavioural Neurobiology, Faculty of Earth and Life Sciences (FALW), Vrije Universiteit Amsterdam, De Boelelaan 1087, Room B-256, 1081 HV Amsterdam, The Netherlands.
J Pharmacol Exp Ther. 2005 Mar;312(3):905-16. doi: 10.1124/jpet.104.075820. Epub 2004 Nov 10.
The present study was performed to 1) determine heart rate (HR) effects mediated through central corticotropin-releasing factor receptor subtypes 1 (CRF(1)) investigate and 2 (CRF(2)) and 2) to the contribution of endogenous CRF to baseline HR and its fear-induced adjustment in freely moving mice. CRF ligands were injected into both lateral ventricles (i.c.v.) 15 min before the presentation of a conditioned auditory fear stimulus (CS). Initial behavioral results suggest an ovine CRF (oCRF)-mediated enhanced baseline fear and mildly enhanced conditioned auditory fear. In contrast, i.c.v. injection of oCRF (35-210 ng/mouse) dose-dependently decreased baseline HR, increased HR variability, and attenuated the CS-induced tachycardia. This effect is suggested to depend on a combined activation of sympathetic and parasympathetic activity referred to as enhanced sympathovagal antagonism. An extreme bradycardia was elicited by oCRF injection into the lower brainstem. All HR effects were probably mediated by CRF(1) because injection of the CRF(2)-selective agonist mouse urocortin II was ineffective, and the baseline bradycardia by i.c.v. CRF was preserved in CRF(2)-deficient mice. Injection of various CRF receptor antagonists including the CRF(2)-selective antisauvagine-30 did not affect the conditioned HR response. This finding suggests that endogenous CRF does not contribute to the fear-mediated tachycardia. Thus, the hypothesis of an involvement of CRF in HR responses of mice to acute aversive stimulation is rejected. Pharmacological evidence points at the involvement of CRF(1) in enhanced sympathovagal antagonism, a pathological state contributing to elevated cardiac risk, whereas the physiological role of the brain CRF system in cardiovascular regulation remains to be determined.
1)确定通过中枢促肾上腺皮质激素释放因子受体亚型1(CRF(1))和2(CRF(2))介导的心率(HR)效应;2)研究内源性CRF对自由活动小鼠的基础心率及其恐惧诱导调节的作用。在呈现条件性听觉恐惧刺激(CS)前15分钟,将CRF配体双侧脑室注射(脑室内注射,i.c.v.)。初步行为学结果表明,羊CRF(oCRF)介导基础恐惧增强和条件性听觉恐惧轻度增强。相反,脑室内注射oCRF(35 - 210 ng/小鼠)剂量依赖性降低基础心率,增加心率变异性,并减弱CS诱导的心动过速。这种效应可能依赖于交感神经和副交感神经活动的联合激活,即增强的交感迷走神经拮抗作用。向下脑干注射oCRF可引发极度心动过缓。所有心率效应可能由CRF(1)介导,因为注射CRF(2)选择性激动剂小鼠尿皮质素II无效,且脑室内注射CRF引起的基础心动过缓在CRF(2)缺陷小鼠中依然存在。注射包括CRF(2)选择性抗蛙皮素 - 30在内的各种CRF受体拮抗剂均不影响条件性心率反应。这一发现表明内源性CRF对恐惧介导的心动过速无作用。因此,CRF参与小鼠对急性厌恶刺激的心率反应这一假说被否定。药理学证据表明CRF(1)参与增强的交感迷走神经拮抗作用,这是一种导致心脏风险升高的病理状态,而脑CRF系统在心血管调节中的生理作用仍有待确定。